Embedded in the article on the publication of the company's press release about its study being published in the International Wound Journal were comments about the company's Purion processed allografts acting as a "stem cell magnet" I think this will prove to be huge and open a ton of new avenues for the company. I believe they know this and have filed their shelf offering in preparation of having funds available for some wild growth. I want to hear if any of the analysts on the conference call will inquire about it.
You are so right about this revelation going over every one's head. When I listened to the conference call, analysts were more concerned about getting the CMS approvals than they were about the potential for the stem cell magnet. ( I did not read the transcripts so I some of my memory is wrong I apologize in advance ) The one analyst (from Northland I believe) who asked a few questions and even talked about the potential of the "magnet" if he :thinks out of the box" only raised his price target to $7 from $6. And despite a PR release from the company about its study being published in the International Wound Journal nobody is picking up on it. The implications of this discovery are mind-boggling. Let's see what the peer review brings.
I saw the same note, not only is mdxg going to be known As a regenerative company but we will be entering the area of triggering the immune system, and that means a cure for cancer and other applications could be enhanced, huge, huge, huge!